de Abreu Ariane de Jesus Lopes, Ventura Deisy de Freitas Lima, Waldman Eliseu Alves
Faculdade de Saúde Pública Universidade de São Paulo Brasil Faculdade de Saúde Pública, Universidade de São Paulo, Brasil.
Rev Panam Salud Publica. 2025 Apr 28;49:e42. doi: 10.26633/RPSP.2025.42. eCollection 2025.
The COVID-19 pandemic exposed flaws in global public health emergency preparedness and response plans, highlighting the urgency of ensuring equitable access to health technologies and products, especially in low- and middle-income countries (LMICs). In this context, the World Health Organization is negotiating a Pandemic Accord to strengthen global governance, reduce disparities between high-income countries (HICs) and LMICs, and improve prevention and response to future pandemics.Articles 10 and 11 of the most recent version of the proposal (14 December 2024) address diversified and sustainable production of health products, as well as the transfer of technology and know-how, with a focus on LMICs. These provisions promote national capacity-building for the production of inputs, transparency in licensing agreements, and the use of TRIPS Agreement flexibilities on intellectual property. However, gaps remain, such as a lack of clear definitions for pandemics and health products, and an emphasis on voluntary measures.Brazil, a traditional vaccine producer, can potentially benefit from the new international context, strengthening its technological capacity and improving its health security ecosystem. Strategic measures include the adoption of sectoral and cross-sectoral policies, participation in technology and knowledge transfer initiatives, and investment in human resources training. These actions will contribute to equity in access to vaccines, especially for vulnerable populations, in line with the objectives of the Immunization Agenda 2030 and the lessons learned from the response to COVID-19.
新冠疫情暴露了全球突发公共卫生事件防范和应对计划中的缺陷,凸显了确保公平获取卫生技术和产品的紧迫性,尤其是在低收入和中等收入国家(LMICs)。在此背景下,世界卫生组织正在谈判一项《大流行协定》,以加强全球治理,缩小高收入国家(HICs)与低收入和中等收入国家之间的差距,并改进对未来大流行的预防和应对。提案最新版本(2024年12月14日)的第10条和第11条涉及卫生产品的多样化和可持续生产以及技术和专门知识的转让,重点是低收入和中等收入国家。这些条款促进了投入品生产的国家能力建设、许可协议的透明度以及对《与贸易有关的知识产权协定》(TRIPS协定)知识产权灵活性的运用。然而,仍存在差距,例如对大流行和卫生产品缺乏明确界定,以及强调自愿措施。巴西作为传统疫苗生产国,有可能从新的国际环境中受益,增强其技术能力并改善其卫生安全生态系统。战略措施包括采取部门和跨部门政策、参与技术和知识转让倡议以及投资于人力资源培训。这些行动将有助于实现疫苗获取的公平性,特别是对于弱势群体,这符合《2030年免疫议程》的目标以及从应对新冠疫情中吸取的经验教训。